Putting numbers on the global venture slowdown

“Tell me something I don’t know,” was my first reaction when reports on venture capital in 2022 hit my inbox this month. It is pretty clear by now that there was a slowdown, so what’s the point of harping on about it as we enter a new year?

The point, as often with data, is that we can now confirm what was merely intuition until Q4 actually closed: 2022 saw fewer exits and venture deals than 2021.

The Exchange explores startups, markets and money.

Read it every morning on TechCrunch+ or get The Exchange newsletter every Saturday.

If we had to retain only one fact, it would be the decline in capital invested in startups last year. According to CB Insights, whose State of Venture report is one of our sources today, total venture funding in 2022 amounted to $415.1 billion, 35% less than in 2021.

According to the PitchBook-NVCA Venture Monitor report, deal count was more stable, with 2022’s estimated deal count approaching 2021’s figure. But looking at quarterly data reveals that Q4 had the lowest deal count of 2022, which doesn’t necessarily bode well for 2023.

Putting numbers on the global venture slowdown by Anna Heim originally published on TechCrunch



from TechCrunch https://ift.tt/1HDs3Fw
via IFTTT

Comments

Post a Comment

Popular posts from this blog

6 investors discuss why AI is more than just a buzzword in biotech

As ChatGPT has so aptly demonstrated, AI is now truly entering the mainstream consciousness. That’s why we weren’t very surprised when a slew of investors told us they rarely see a biotech startup that doesn’t incorporate AI in some form or other these days. “Most of the companies we have seen have an AI component to support the discovery or development processes,” Francisco Dopazo, a general partner at Humboldt Fund told TechCrunch recently. But despite becoming quite the buzzword, AI’s apparent ubiquity in biotech isn’t actually driving deal flow or higher valuations. So to get a better idea of how AI is affecting biotech in 2022, we asked six investors to tell us what they look for in a biotech startup today. For Franck Lescure, a partner at Elaia Partners, in biotech, having an AI component isn’t an automatic deal closer. “We do not favor biotech startups with extant AI over those without: Bio-revolution is not only digital. Digital is one tool; the other major tool is the livin
Read more

Voiceflow, a Canada-based SaaS platform that lets companies launch their own voice and chat bots, raises $20M Series A led by Felicis Ventures (Igor Bosilkovski/Forbes)

Image
Igor Bosilkovski / Forbes : Voiceflow, a Canada-based SaaS platform that lets companies launch their own voice and chat bots, raises $20M Series A led by Felicis Ventures   —  Canadian collaborative conversational AI tool Voiceflow announced today that it has raised $20 million in a Series A round led by Felicis Ventures. from Techmeme https://ift.tt/3rFQ9St via IFTTT
Read more

Ex-staffers say Twitter's mass firing of security staff and growing reliance on automation will help China and other authoritarian regimes in silencing critics (Adam Rawnsley/Rolling Stone)

Image
Adam Rawnsley / Rolling Stone : Ex-staffers say Twitter's mass firing of security staff and growing reliance on automation will help China and other authoritarian regimes in silencing critics   —  Elon's mass firing of security staff and increased reliance on automation is going to make it easier for tyrants to shout … from Techmeme https://ift.tt/xQsF2ef via IFTTT
Read more